- Company
- Domestic supply of Nimbex has been discontinued
- by Oct 27, 2020 06:11am
- According to the distribution industry on the 23rd, 'Mitsubishi Tanabe, which is in charge of distribution and sales of Nimbex in Korea, sent an official letter to the wholesale industry and announced that Nimbex will cease distribution in Korea on November 3rd. Mitsubishi Tanabe said, "Due to internal circumstances such as the productivit
- Company
- Pfizer’s EGFR TKI Vizimpro to get listed by the year-end
- by Eo, Yun-Ho Oct 26, 2020 06:15am
- Pfizer’s epidermal growth factor receptor (EGRF) tyrosine kinase inhibitors (TKI) Vizimpro (dacomitini) is predicted to get listed for National Health Insurance (NHI) reimbursement within this year. The pharmaceutical industry sources reported the fifth ERGR TKI Vizimpro is to begin the pricing negotiation with National Health Insurance
- Company
- Whanin·Myung In successfully evaded patent for Fycompa
- by Kim, Jin-Gu Oct 26, 2020 06:15am
- Myung In and Whanin succeeded in circumventing some of the patents of 'Fycompa (Perampanel anhydrous)', an epilepsy treatment. The two companies will be able to launch generics as early as October 2023. On the 21st, the Intellectual Property Trial and Appeal Board issued a trial decision for ``establishment of claim'' at the judgment on t
- Company
- CKD top candidate for Amgen’s Evenity co-promotion partner
- by Oct 26, 2020 06:14am
- As Amgen’s novel osteoporosis drug Evenity (romososumab) is expected to get listed for reimbursement by the end of the year, the multinational company is reportedly seeking for a co-promotion company. The current partner company for Prolia (denosumab) co-promotion, Chong Kun Dang, is considered as the strongest candidate. According
- Company
- Rosuzet soars despite COVID-19, Lipitor tops market again
- by An, Kyung-Jin Oct 23, 2020 09:46am
- On Oct. 23, a pharmaceutical market research firm UBIST reported a dyslipidemia treatment Lipitor defended its top spot again in the outpatient prescription market this third quarter reaching a cumulative prescription volume of 140.1 billion won. Compared to the third quarter last year at 143.1 billion won, the figure dipped 2 percent, but its p
- Company
- Rinvoq is in the process of prescribing general hospitals
- by Eo, Yun-Ho Oct 23, 2020 09:44am
- The third JAK inhibitor Rinvoq was received for prescription in general hospital. The synergy is expected as the application of insurance benefits became visible from November. According to related industries, AbbVie Korea recently concluded a drug price negotiation between the NHIS and the oral autoimmune disease treatment Rinvoq (Upadaci
- Company
- Kisqali to be listed November starting three-way competition
- by Eo, Yun-Ho Oct 22, 2020 06:32am
- The cyclin-dependent kinase 4/6 (CDK4/6) inhibitor market is expanded to a three-way competition. A pharmaceutical industry source reported, Novartis’ hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer treatment Kisqali (ribociclib) has concluded the pricing negotiation with Nati
- Company
- Samsung-AZ joint venture contemplates on Mabthera biosimilar
- by Kim, Jin-Gu Oct 22, 2020 06:30am
- A subsidiary of Samsung Biologics, Archigen Biotech (“Archigen”) has successfully completed clinical trials but it has not yet disclosed its further plan on the product in development. While Archigen’s sole portfolio is a Mabthera (rituximab) biosimilar in development, the industry is paying attention to the correlation between Archi
- Company
- Submission of α-GPC clinical reevaluation plan is imminent
- by Chon, Seung-Hyun Oct 20, 2020 06:35am
- Pharmaceutical companies are preparing in earnest with two months ahead of the deadline for submitting data for the clinical reevaluation plan of Choline alfoscerate. They are contemplating the indications for clinical trials and clinical work. The method of paying the cost of clinical trials and the process of selecting participating companies
- Company
- Can novel bone-builder Evenity win reimbursement this year?
- by Eo, Yun-Ho Oct 20, 2020 06:34am
- Apparently, a novel bone-builder Evenity is making its last push to nab the National Health Insurance (NHI) benefit by the end of the year. The South Korean pharmaceutical industry sources reported, Amgen Korea and National Health Insurance Service (NHIS) have recently initiated a pricing negotiation on an osteoporosis drug Evenity (rom
